System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to CD255 / TWEAK

CARL-1 (IgG3)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
  11-756-C025 purified 0.025 mg yes choose region PDF datasheetHTML datasheet buy
  11-756-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  12-756-C100 low endotoxin 0.1 mg yes choose region PDF datasheetHTML datasheet buy
  1P-756-T025 PE 25 tests yes choose region PDF datasheetHTML datasheet buy
  1P-756-T100 PE 100 tests yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order

Background

CD255 / TWEAK (TNF-related weak inducer of apoptosis), a type II transmembrane protein expressed as membrane-bound and secreted form, can induce apoptosis in many tissues and cell lines through its receptor CD266 / TWEAK R. On the other hand, in endothelial cells this interaction can induce proliferation and promote angiogenesis including neovascularization of tumours. CD255 can act in a juxtacrine manner to initiate cellular responses, and induces secretion of pro-inflammatory cytokines. Besides CD266, CD255 may also bind to DR3.

Specificity

The mouse monoclonal antibody CARL-1 recognizes CD255 / TWEAK, a type II transmembrane protein of the TNF superfamily able to weakly induce apoptosis in many cell types.

Regulatory Status

Immunogen

human CD255-transfected 2PK-3 cells

Species Reactivity:

  • Human

Negative Species:

Applications:

  • Flow Cytometry
  • Immunohistochemistry
  • Functional Application
    neutralization
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

  • *Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H: Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med. 2000 Nov 6;192(9):1373-80. [Abstract] [Full Text]
  • *Brown SA, Ghosh A, Winkles JA: Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem. 2010 Jun 4;285(23):17432-41. [Abstract] [Full Text]
  • *Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S: TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem. 2003 Sep 19;278(38):36005-12. [Abstract] [Full Text]
  • *Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T: Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol. 2006 Dec;146(3):540-9. [Abstract] [Full Text]
  • *Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1;170(1):341-8. [Abstract] [Full Text]
  • *Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan;2(1):103-108 [Abstract] [Full Text]
  • For research use only. Not for drug, diagnostic or other use.

    Example Data

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at www.exbio.cz.
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy